Industry News
Biotechnology Industry News
Astellas Pharma has become the…
Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune disease that still lacks any dedicated medicines.
One of the world’s leading…
One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life Sciences VI (BLXS VI) fund, which is 40% larger than its predecessor.
Autoimmune specialist Aurinia,…
Autoimmune specialist Aurinia, which named Kevin Tang as its new CEO last week, is acquiring Kezar after the latter company received promising feedback from the FDA. Tang previously made an unsuccessful attempt in 2024 to
Royalty Pharma has made another…
Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune disease treatment, with
Connect Biopharma has reported…
Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is better than Dupixent.
Despite the primary endpoint hit,…
Despite the primary endpoint hit, the candidate's inability to meet investors’ expectations cast a shadow over the results.
Kardigan’s tonlamarsen reduced a…
Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure.
Biogen’s lupus drug candidate…
Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of the autoimmune disease.
Kailera Therapeutics—one of the…
Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.
In the early 1960s, Norwegian…
In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally discovered a lipoprotein with perplexing properties.
KBP Biosciences is looking to…
KBP Biosciences is looking to reclaim ownership of the ill-fated heart drug ocedurenone from Novo Nordisk following a botched $1.3 billion deal and fraud allegations, Fierce Biotech has learned.
Eli Lilly and AI-powered…
Eli Lilly and AI-powered clinical-stage biotech Insilico Medicine have announced a back-loaded, $2.75 billion biobucks drug discovery collaboration that will extend the Big Pharma company’s access to Insilico’s AI engine to pursue novel therapeutics.
AstraZeneca isn’t letting a…
AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it
Otsuka Pharmaceutical has acquired…
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to $525 million in milestone payments tied to assets in
Takeda has posted phase 3 data on…
Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share with companies including Bristol Myers Squibb and Johnson &
Merck & Co. has lifted the lid…
Merck & Co. has lifted the lid on the third successful phase 3 trial of its PCSK9 inhibitor, showing the edge the cardiovascular disease prospect has over other oral non-statin therapies.
Boehringer Ingelheim may have been…
Boehringer Ingelheim may have been on a spending spree for licensing deals so far this year—but the German pharma has plenty more items on its shopping list.
AstraZeneca’s chronic…
AstraZeneca’s chronic obstructive pulmonary disease drug candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and Sanofi.
Novartis has penned a $2 billion…
Novartis has penned a $2 billion deal for a biotech whose next-gen anti-IgE program could offer a worthy successor to Xolair.
Seasoned biotech takeover titan…
Seasoned biotech takeover titan Kevin Tang has struck again. After serving as board chair of Aurinia since 2024, Tang has now ascended to the CEO spot and swapped out the company’s C-suite with a cadre